Actively Recruiting
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Led by Mercy Medical Center · Updated on 2024-11-19
200
Participants Needed
1
Research Sites
428 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
CONDITIONS
Official Title
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Cirrhosis patients aged 18 years or older attending the hepatology clinic at Mercy Medical Center between 09/2020 and 07/2021
- Patients without immunity against Hepatitis B, defined as anti-HBs titer less than 10 mIU/ml
You will not qualify if you...
- History of serious allergic reaction to any hepatitis B vaccine, its components, or yeast
- Previous exposure to hepatitis B virus
- Patients who have undergone liver transplant
- Under 18 years of age
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mercy Medical Center
Baltimore, Maryland, United States, 21202
Actively Recruiting
Research Team
C
CHAU TO, MD
CONTACT
P
Paul Thuluvath, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here